Nothing Special   »   [go: up one dir, main page]

Yoshizawa et al., 2003 - Google Patents

Studies on the generation and maintenance of mucosal cytotoxic T lymphocytes against human immunodeficiency virus type 1 Gag in mice

Yoshizawa et al., 2003

Document ID
4518075244357046401
Author
Yoshizawa I
Mizuochi T
Ogata A
Murakami M
Yagaita H
Takahashi Y
Mizuochi T
Takemori T
Tsunetsugu-Yokota Y
Publication year
Publication venue
AIDS research and human retroviruses

External Links

Snippet

Aspects of the generation and maintenance of mucosal immunity against human immunodeficiency virus type 1 (HIV-1) were examined. Mice were immunized either intranasally or intrarectally with recombinant HIV-1 Gag p24 protein plus cholera toxin …
Continue reading at www.liebertpub.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Yoshizawa et al. Studies on the generation and maintenance of mucosal cytotoxic T lymphocytes against human immunodeficiency virus type 1 Gag in mice
Calarota et al. Cellular HIV-1 immune responses in natural infection and after genetic immunization
Mohammad Correlates of cytotoxic T lymphocyte vaccine-induced control against Simian immunodeficiency virus (SIV)
Inizan Human Immunodeficiency Virus Type I subverts T cell extracellular matrix to shelter cell-associated infectivity in a viral biofilm
Victoriano et al. WEPDA0202: Role of UHRF1 in transcriptional regulation and maintenance of HIV‐1 latency
Forsman Characterisation of llama antibody fragments able to act as HIV-1 entry inhibitors
Fitzgerald et al. TUAA0105: A universal nanoparticle cell secretion capture assay for the study of HIV‐1‐positive tissues
Vaccari et al. WEAA0101: Characterization of early gene expression profile in the blood of macaques immunized a Thai trail‐like vaccine
Thanh et al. THPDA0101: Peripheral blood monocytes contribute to the immune reconstitution inflammatory syndrome (IRIS): is the complement system emerging to the spotlights?
Wacleche et al. TUPDA0101: The colocalization potential of HIV‐specific CD8+ and CD4+ T cells is mediated by integrin β7 but not CCR6 and regulated by retinoic acid
Santos‐Oliveira et al. THPDA0102: Cytokine storm in leishmania/HIV‐1 co‐infected patients can be caused by LPS and leishmania infection
Nawaz et al. WEAA0105: The HIV‐1 envelope protein gp120 mimics MAdCAM and VCAM in binding to Integrin‐α: 4: β: 7
Thaisri et al. THPDA0105: Prevalence and genotypic variability of TT virus are extremely high in HIV‐1‐infected adults in the Lampang HIV‐1 cohort in northern Thailand
Karlsson et al. Jellis, AT Profy, JR Rusche, DP Bolognesi, SD Putney, and TJ Matthews. 1989. Principal ncutralizing domain of the lhuman immunodcfi-cicncy virus typc 1 cnvclopc protcin. Proc. Natl. Acad. Sci. USA 86: 6768–
Roan et al. MOAA0101: The effect of liquefaction on the ability of semen and semen amyloid fibrils to enhance HIV infection
Chang et al. THPDA0202: Hematopoietic stem cell gene therapy targeting HIV‐1 based on lentiviral CCR5Δ32 and multiple microRNAs
Doitsh et al. WEAA0204: HIV‐induced CD4 T cell depletion: an innate host defense gone awry?
Trinité et al. MOLBA01: Unintegrated HIV‐1 generates an inducible reservoir of replication competent virus in nonproliferating CD4:+: T cells
Madlala et al. MOPDA0103: Association of polymorphisms in the regulatory region of cyclophilin A gene (PPIA) with disease progression and gene expression levels
Lajoie et al. TUPDB0201: Evidence for T cell immune quiescence in the genital mucosa of HIV exposed seronegative commercial sex workers
Peterson et al. WEPDA0101: HLA class I associations with rates of HIV‐1 seroconversion and disease progression in the Pumwani sex worker cohort
De Pasquale et al. THPDA0204: Apobec3G levels are inversely associated with resting CD4+ T memory cell integrated provirus: in vivo: and infectivity of reactivated HIV‐1: ex vivo
Luo et al. WEAA0102: A novel HIV vaccine approach: targeting the protease cleavage sites of HIV‐1
French et al. MOAA0204: Natural control of HIV infection is associated with an isotype switched IgG antibody response to HIV core antigens in patients with ‘non‐protective’HLA‐B alleles
Ruel et al. THPDA0205: CXCR4‐tropism is associated with the preferential establishment of an HIV‐reservoir in naïve CD4+ T cells among HIV‐positive Ugandan children receiving antiretroviral therapy